Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
Inventors
Wang, Jing • Patterson, Troy David • TIAN, ZE
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject: (a) a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or an acyl group; and (b) a PD-1 signaling inhibitor; wherein the compound of Formula I or pharmaceutically acceptable salt thereof and the PD-1 signaling inhibitor are administered in amounts which in combination are therapeutically effective. The invention further provides a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, a PD-1 signaling inhibitor and a pharmaceutically acceptable carrier or excipient.
Core Innovation
The invention provides a cancer treatment combination therapy comprising administering, to a subject in need thereof, a pharmaceutically acceptable salt of a compound of a specified formula and a PD-1 signaling inhibitor, wherein the pharmaceutically acceptable salt of the compound and the PD-1 signaling inhibitor are administered in amounts which in combination are therapeutically effective. The compound is described as a PI3K/HDAC-related compound of Formula I, with structural definitions and specific named examples including Compound 1.
The document characterizes the compound through biological evaluation including PI3K isoform activity and HDAC inhibitory activity. Compound 1 is described with PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ activity, and with HDAC inhibitory activity across HDAC1 to HDAC11.
For in vivo evaluation, the document describes mouse xenograft efficacy in CT26.WT colon carcinoma and A20 models, reporting tumor growth inhibition when Compound 1 is combined with anti-PD-1. The combination is described as producing near-complete or markedly enhanced tumor growth inhibition versus either monotherapy in the cited models, and the document includes pharmaceutical compositions containing the Formula I compound or pharmaceutically acceptable salts together with a PD-1 inhibitor and pharmaceutically acceptable carriers or excipients.
Claims Coverage
The independent claim covers a treatment method for colon carcinoma using a combination of a pharmaceutically acceptable salt of a specified formula compound and a PD-1 signaling inhibitor, administered at amounts that together are therapeutically effective. The claim set includes dependent refinements that specify PD-1-pathway targeting, antibody modality options, named inhibitor options, and particular salt types and combination formulation aspects.
Treating colon carcinoma with a therapeutically effective combination of a pharmaceutically acceptable salt and a PD-1 signaling inhibitor
A method of treating colon carcinoma in a subject in need thereof, comprising administering a pharmaceutically acceptable salt of a compound of the specified formula and a PD-1 signaling inhibitor, wherein the pharmaceutically acceptable salt and the PD-1 signaling inhibitor are administered in amounts which in combination are therapeutically effective.
PD-1-pathway inhibition by PD-1, PD-L1, or PD-L2 targeting
The PD-1 signaling inhibitor inhibits one or more of PD-1, PD-L1, and PD-L2.
Antibody modality for PD-1 signaling inhibition
The PD-1 signaling inhibitor is provided as an anti-PD-1, anti-PD-L1, or anti-PD-L2 monoclonal antibody.
Selected anti-PD-1 pathway inhibitor options
The PD-1 signaling inhibitor is selected from pembrolizumab, nivolumab, atelolizumab, avelumab, durvalumab, or pidilizumab.
Combined administration as a single pharmaceutical composition
The pharmaceutically acceptable salt of the compound and the PD-1 signaling inhibitor are administered together in a single pharmaceutical composition.
Specific salt types for the compound
The pharmaceutically acceptable salt is a methanesulfonate salt or a benzenesulfonate salt.
Overall, the claim coverage centers on a colon carcinoma treatment using a therapeutically effective combination of a pharmaceutically acceptable salt of the specified formula compound with a PD-1 signaling inhibitor, with dependent claims further narrowing the PD-1-pathway target set, antibody modality and named inhibitor options, and specifying combination formulation and particular salt types.
Stated Advantages
Therapeutically effective combination amounts for treating colon carcinoma.
PI3K/HDAC inhibitory activity and antiproliferative activity.
Oral bioavailability and tumor uptake/pharmacodynamic activity in xenograft tumor models.
Near-complete or markedly enhanced tumor growth inhibition in CT26.WT and A20 mouse xenograft models when the compound is combined with anti-PD-1 versus either monotherapy.
A safety-related Ames signal is reported for Compound 1.
Documented Applications
Combination therapy for treating colon carcinoma in a subject in need thereof using a pharmaceutically acceptable salt of a Formula I compound together with a PD-1 signaling inhibitor.
Mouse xenograft evaluation in CT26.WT colon carcinoma and A20 models using Compound 1 combined with anti-PD-1, reporting tumor growth inhibition outcomes.
Use of the Formula I compound together with PD-1 pathway inhibition in xenograft tumor models with reported tumor uptake/pharmacodynamic activity and antitumor activity.
Interested in licensing this patent?